Skip to Main Content

Paper Details

Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria.
New England Journal of Medicine
25
2022
Author NameAffiliation
Adrian B McDermottFrom the Vaccine Research Center (R.L.W., Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, the U.S. Public Health Service Commissioned Corps, Walter Reed Army Institute of Research, J.R. Murphy) - all in Maryland the Ragon Institute, Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, MA (A.H.I.) and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego
Sandeep NarpalaFrom the Vaccine Research Center (R.L.W., Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, the U.S. Public Health Service Commissioned Corps, Walter Reed Army Institute of Research, J.R. Murphy) - all in Maryland the Ragon Institute, Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, MA (A.H.I.) and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego
John R MascolaFrom the Vaccine Research Center (R.L.W., Division of Clinical Research (Z.H.), National Institute of Allergy and Infectious Diseases, National Institutes of Health, the U.S. Public Health Service Commissioned Corps, Walter Reed Army Institute of Research, J.R. Murphy) - all in Maryland the Ragon Institute, Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, MA (A.H.I.) and the School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego
  • 1 - 3

Datasets